Sophia Genetics, MSK Plan NYC Precision Oncology Hub
Sophia Genetics and Memorial Sloan Kettering Cancer Center have signed a memorandum of understanding to create a joint venture that would establish a precision medicine hub in New York City, according to MobiHealthNews. The plan pairs MSK's deep clinical and genomic expertise with Sophia Genetics' SOPHiA DDM platform, which uses artificial intelligence to analyze genomic and multimodal data and help match cancer patients to targeted therapies.
The move reflects a broader industry push to turn vast troves of genomic and clinical data into faster, more accurate cancer care. Precision oncology depends on interpreting complex tumor profiles at scale, and partnerships between academic cancer centers and data-analytics companies are becoming a common route to do that work without building everything in-house.
An MOU is a preliminary step, not a finalized deal, so terms, funding, and timing remain to be settled. If completed, the hub would give both partners a platform to commercialize data-driven diagnostics and expand access to advanced genomic testing.
Sources